Showing 1 - 4 results of 4 for search 'Peter Bader', query time: 0.02s Refine Results
  1. 1
    CAR-CIK vs. CAR-T: benchmarking novel cytokine-induced killer cells as solid tumor immunotherapy in ErbB2+ rhabdomyosarcoma

    CAR-CIK vs. CAR-T: benchmarking novel cytokine-induced killer cells as solid tumor immunotherapy in ErbB2+ rhabdomyosarcoma by Laura M. Moser, Laura M. Moser, Laura M. Moser, Laura M. Moser, Laura M. Moser, Catrin Heim, Sebastian E. Koschade, Sebastian E. Koschade, Sebastian E. Koschade, Sebastian E. Koschade, Sebastian E. Koschade, Philipp Wendel, Philipp Wendel, Philipp Wendel, Philipp Wendel, Süleyman Bozkurt, Sabine Harenkamp, Hermann Kreyenberg, Hermann Kreyenberg, Michael Merker, Michael Merker, Christian Münch, Christian Münch, Christian Münch, Elise Gradhand, Meike Vogler, Meike Vogler, Meike Vogler, Evelyn Ullrich, Evelyn Ullrich, Evelyn Ullrich, Evelyn Ullrich, Evelyn Ullrich, Halvard Bönig, Halvard Bönig, Jan-Henning Klusmann, Jan-Henning Klusmann, Jan-Henning Klusmann, Jan-Henning Klusmann, Peter Bader, Peter Bader, Peter Bader, Peter Bader, Peter Bader, Winfried S. Wels, Winfried S. Wels, Winfried S. Wels, Eva Rettinger, Eva Rettinger, Eva Rettinger, Eva Rettinger, Eva Rettinger

    Published 2025-02-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Case report: Advanced age at transplantation and pre-emptive treatment with dupilumab in DOCK8 deficiency

    Case report: Advanced age at transplantation and pre-emptive treatment with dupilumab in DOCK8 deficiency by Sophia Trombello, Sophia Trombello, Andrea Jarisch, Andre Willasch, Eva Rettinger, Julia Fekadu-Siebald, Dirk Holzinger, Dirk Holzinger, Roland Adelmann, Peter Bader, Shahrzad Bakhtiar

    Published 2025-01-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Multinational retrospective analysis of bridging therapy prior to chimeric antigen receptor t cells for relapsed/refractory acute lymphoblastic leukemia in children and young adults

    Multinational retrospective analysis of bridging therapy prior to chimeric antigen receptor t cells for relapsed/refractory acute lymphoblastic leukemia in children and young adult... by Maike Breidenbach, Peter Bader, Andishe Attarbaschi, Claudia Rossig, Roland Meisel, Markus Metzler, Marion Subklewe, Fabian Mueller, Paul-Gerhardt Schlegel, Irene Teichert von Lüttichau, Jean-Pierre Bourquin, Gabriele Escherich, Gunnar Cario, Peter Lang, Ramona Coffey, Arend von Stackelberg, Semjon Willier, Brigitte Strahm, Christina Peters, Tobias Feuchtinger

    Published 2025-01-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Comparable outcomes after busulfan- or treosulfan-based conditioning for allo-HSCT in children with ALL: results of FORUM

    Comparable outcomes after busulfan- or treosulfan-based conditioning for allo-HSCT in children with ALL: results of FORUM by Krzysztof Kalwak, Laura M. Moser, Ulrike Pötschger, Peter Bader, Katharina Kleinschmidt, Roland Meisel, Jean-Hugues Dalle, Akif Yesilipek, Adriana Balduzzi, Gergely Krivan, Evgenios Goussetis, Raquel Staciuk, Petr Sedlacek, Herbert Pichler, Peter Svec, Melissa Gabriel, Tayfun Güngör, Ernest Bilic, Jochen Buechner, Marleen Renard, Kim Vettenranta, Marianne Ifversen, Cristina Diaz-de-Heredia, Jerry Stein, Jacek Toporski, Marc Bierings, Christina Peters, Marc Ansari, Franco Locatelli

    Published 2025-02-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: